ANP32C Monoclonal Antibody (OTI10A10), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA527188-Each-of-1 | In Stock | ₹ 52,198.50 |
PIMA527188 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 52,198.50
GST (18%): ₹ 9,395.73
Total Price: ₹ 61,594.23
Antigen
ANP32C
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3
Gene Accession No.
O43423
Gene Symbols
ANP32C
Immunogen
Full length human recombinant protein of ANP32C produced in E.coli
Quantity
100μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG2a
Applications
Immunohistochemistry (Paraffin), Western Blot
Clone
OTI10A10
Conjugate
Unconjugated
Gene
ANP32C
Gene Alias
acidic (leucine-rich) nuclear phosphoprotein 32 family, member C; acidic (leucine-rich) nuclear phosphoprotein 32 family, pseudogene; acidic leucine-rich nuclear phosphoprotein 32 family member C; acidic nuclear phosphoprotein 32 family member C; ANP32C; Anp32cl; Anp32c-ps; Anp32-ps; EG448829; Phosphoprotein 32-related protein 1; pp32 related 1; PP32R1; Tumorigenic protein pp32r1
Host Species
Mouse
Purification Method
Affinity Chromatography
Regulatory Status
RUO
Gene ID (Entrez)
23520
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Related Products
Description
- ANP32C (acidic (leucine-rich) nuclear phosphoprotein 32 family, member C), also known as PP32R1 (phosphoprotein 32-related protein 1) or tumorigenic protein pp32r1, is a 234 amino acid protein that contains 4 leucine-rich repeats and belongs to the ANP32 family
- ANP32C shares 87.7% amino acid sequence identity with ANP32A, a tumor suppressor that inhibits a variety of cancers, such as prostate and breast cancers
- Although similar to ANP32A, ANP32C is tumorigenic and is expressed in activated stem cells, such as mobilized CD34+ cells and cord blood CD34+ cells, but not in resting bone marrow CD34+ cells
- ANP32C is also expressed in a variety of neoplastic cell lines, mainly in prostatic adenocarcinoma cell lines, but not in normal protastic tissue, and may also modulate the oncogenic potential of human prostate cancer.